Clindamycin HCl

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Clindamycin HydroHClide 通过作用于 50S 核糖体来抑制蛋白质合成。

Clindamycin Hydrochloride inhibits protein synthesis by acting on the 50S ribosomal. It is the hydrochloride salt form of clindamycin, a semi-synthetic, chlorinated broad-spectrum antibiotic produced by chemical modification of lincomycin. Clindamycin hydrochloride is used as a solid in capsules.(In Vitro):Clindamycin hydrochloride results in fast absorption after oral administration in dogs, with a mean absorption time (MAT) of 0.87 hour, and bioavailability is 72.55%. Clindamycin hydrochloride results in total clearance (CL) of Clindamycin after both IV and oral administration (0.503 vs. 0.458 L/h/kg) in dogs. Clindamycin hydrochloride results in volume of distribution at steady-state (IV) at 2.48 L/kg, indicating a wide distribution of clindamycin in body fluids and tissues. Clindamycin serum concentrations after IV and oral administration remain above 0.5 μg/mL approximately for 10 hours. Clindamycin hydrochloride significantly reduces oral malodor from the dogs' baseline levels through 42 days. Clindamycin hydrochloride also results in significant reductions in dental plaque, dental calculus, and gingival bleeding in dogs. Clindamycin hydrochloride (2.5 mg/Lb), after ultrasonic scaling, root planing, and polishing (USRP), has a significant effect on plaque and pocket depth measures of periodontal disease but not on gingivitis in canine. Clindamycin hydrochloride results in complete remission ratio of 71.4% (15/21) in dogs with canine superficial bacterial pyoderma after treat within 14 to 28 days.

——

——

——

Wnt/Notch/Hedgehog

Porcupine

Others

Infection

——

21462-39-5

461.44

C18H33ClN2O5S·HCl

>98% (HPLC)

DMSO : ≥ 43 mg/mL; 93.19 mM

[C@@H]1(O[C@@H]([C@@H]([C@H]([C@H]1O)O)O)SC)[C@H](NC(=O)[C@H]1N(C[C@@H](C1)CCC)C)[C@@H](Cl)C.Cl

——

(-20℃)

With Ice Pack

≥ 2 years